RankingsLogo

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Gilead Sciences, Inc. is a biopharmaceutical company that researches and develops treatments and drugs. Its work has helped to treat HIV/AIDS, heart and liver diseases, cancers, respiratory diseases including COVID-19, and more.

Ticker: GILD

Humankind Value: $121.6 B

Revenue: $27.2 B

Market Cap: $103.7 B

Badge100_2023
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Gilead Sciences, Inc. operates in a manner that is a net positive for humanity. The greatest contributors to this positive outcome are Healthcare R&D ($97.6 B), Pharmaceuticals ($19.0 B), and Economic Value ($7.5 B). Out of every company we have analyzed, Gilead Sciences, Inc. is in the top ten for Healthcare R&D and Pharmaceuticals. The value associated with Healthcare R&D and Pharmaceuticals includes the impact of an estimated 2,200,000 additional years lived by people worldwide. The downsides for this company are associated with Biofuel Production (-$3.8 B) and Greenhouse Gases (-$1.1 B). Healthcare R&D, Pharmaceuticals, Economic Value, and Greenhouse Gases are attached to this company as a result of its direct business activities. Biofuel Production is mostly or entirely a result of supply-chain relationships.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings